文献速递肝病消化道肿瘤与早癌

肝癌免疫微环境:肝细胞癌的治疗意义

The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma.
PubMed 文献 · Hepatology · 2023-04-17

肝细胞癌(HCC)占肝癌90%,其进展受免疫系统调控。约半数HCC患者一线接受索拉非尼或仑伐替尼等系统治疗。2020年阿替利珠单抗联合贝伐珠单抗较索拉非尼改善总生存,获FDA批准用于晚期HCC一线治疗。本综述概述HCC免疫微环境、细胞组成、现有免疫治疗及潜在免疫治疗模式。

要点

  • HCC占肝癌90%,约半数患者一线接受索拉非尼或仑伐替尼系统治疗。
  • 2020年阿替利珠单抗联合贝伐珠单抗较索拉非尼改善总生存,获FDA批准为晚期HCC一线治疗。
  • 炎性(热)与非炎性(冷)HCC肿瘤及基因组特征与免疫检查点抑制剂(ICI)应答相关,但尚无额外生物标志物指导临床决策。

核心结论

  • HCC进展受免疫系统调控,肿瘤微环境的分子和细胞特征对HCC发生发展至关重要,仍需更深入表征。
  • 炎性(热)与非炎性(冷)HCC肿瘤及基因组特征与ICI应答相关,但尚无额外生物标志物指导临床决策。
  • 过继性T细胞转移、疫苗接种和病毒治疗等其他免疫靶向策略正在开发中。

研究设计与样本

  • 综述,概述HCC免疫微环境、不同细胞组成、现有免疫治疗及潜在免疫治疗模式。

主要发现

  • 肝为人类第六大常见原发癌症部位和全球第四大癌症相关死亡原因。
  • HCC占肝癌90%。
  • 约半数HCC患者一线接受索拉非尼或仑伐替尼系统治疗。
  • 2020年阿替利珠单抗(抗程序性死亡配体1)联合贝伐珠单抗(抗血管内皮生长因子)较索拉非尼改善总生存,获FDA批准为晚期HCC一线治疗。
  • 炎性(热)与非炎性(冷)HCC肿瘤及基因组特征与ICI应答相关。

关键数值与推荐

  • 肝为人类第六大常见原发癌症部位和全球第四大癌症相关死亡原因。
  • HCC占肝癌90%。
  • 约半数HCC患者一线接受索拉非尼或仑伐替尼系统治疗。
  • 2020年阿替利珠单抗联合贝伐珠单抗较索拉非尼改善总生存,获FDA批准为晚期HCC一线治疗。
  • 炎性(热)与非炎性(冷)HCC肿瘤及基因组特征与ICI应答相关,但尚无额外生物标志物指导临床决策。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The liver is the sixth most common site of primary cancer in humans and the fourth leading cause of cancer-related death in the world. Hepatocellular carcinoma (HCC) accounts for 90% of liver cancers. HCC is a prevalent disease with a progression that is modulated by the immune system. Half of the patients with HCC receive systemic therapies, traditionally sorafenib or lenvatinib, as a first-line therapy. In the last few years, immune-checkpoint inhibitors (ICIs) have revolutionized cancer therapy and have gained an increased interest in the treatment of HCC. In 2020, the combination of atezolizumab (anti-programmed death-ligand 1) and bevacizumab (anti-vascular endothelial growth factor) improved overall survival over sorafenib, resulting in Food and Drug Administration (FDA) approval as a first-line treatment for patients with advanced HCC. Despite these major advances, a better molecular and cellular characterization of the tumor microenvironment is still needed because it has a crucial role in the development and progression of HCC. Inflamed (hot) and noninflamed (cold) HCC tumors and genomic signatures have been associated with response to ICIs. However, there are no additional biomarkers to guide clinical decision-making. Other immune-targeting strategies, such as adoptive T-cell transfer, vaccination, and virotherapy, are currently under development. This review provides an overview on the HCC immune microenvironment, different cellular players, current available immunotherapies, and potential immunotherapy modalities.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Donne R, Lujambio A. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. Hepatology. 2023. PMID: 35989535. doi:10.1002/hep.32740

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。